MAPT and hematocrit: While neuroimaging studies of HT are scarce, some reports suggest a positive role of estrogen therapy on CMRglc (Eberling et al., 2000; Rasgon et al., 2005, 2014; Silverman et al., 2011; Rahman et al., 2020), cerebral blood flow (Maki and Resnick, 2000; Slopien et al., 2003), Aβ deposition (Kantarci et al., 2016a; Rahman et al., 2020) and tau pathology (Wisch et al., 2021).